# Clinical Trial in China

Study · id `cardio:ct-nct05580952` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05580952](<https://clinicaltrials.gov/study/NCT05580952>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05580952

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

## Technical summary

Registry record NCT05580952. Allocation not applicable; no masking; primary purpose treatment. Start 2022-10-14 (anticipated); primary completion 2023-05-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT05580952, source copy `cardio:ctgov-nct05580952-2022-10-14`, retrieved 2026-10-26)
- Planned start: 2022-10-14 (anticipated) (ClinicalTrials.gov record NCT05580952, source copy `cardio:ctgov-nct05580952-2022-10-14`, retrieved 2026-10-26)
- Primary completion: 2023-05-01 (anticipated) (ClinicalTrials.gov record NCT05580952, source copy `cardio:ctgov-nct05580952-2022-10-14`, retrieved 2026-10-26)
- Completion: 2024-05-01 (anticipated) (ClinicalTrials.gov record NCT05580952, source copy `cardio:ctgov-nct05580952-2022-10-14`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05580952, source copy `cardio:ctgov-nct05580952-2022-10-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05580952-2022-10-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Trial in China
- Condition: Diseases of Aortic Valve
- Condition: Aortic Regurgitation Disease
- Intervention (Device): Transcatheter aortic valve replacement
- Lead sponsor: Genesis Medtech Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)

## Provenance

Content hash: 688b62aa934538a2c9c20df10423f915fe0aa5dc8339c58c882dcc095f6bdd3e
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
